Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

Pfizer

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Biological: IMA-638 is a biologic

Study type: Interventional

Funder types: Industry

Identifiers

NCT00410280

B2421001 (Other Identifier)

3174K1-200

Details and patient eligibility

About

Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.

Enrollment: 30 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Inclusion Criteria:

• generally healthy, men and women with mild allergic asthma, aged 18 to 60 years
• only asthma med is short-acting bronchodilator used not more than twice weekly
• FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Exclusion Criteria:

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

30 participants in 1 patient group

1

Other group

Treatment:

Biological: IMA-638 is a biologic